Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Conditions
Brief summary
This trial studies different magnetic resonance imaging (MRI) techniques and their ability to provide clearer pictures of lesions in patients with high grade brain lesions. An MRI is a type of imaging scan. Using different MRI techniques to produce clearer images of the brain may help researchers learn about the features of brain lesions and the effects of chemotherapy and/or radiation therapy.
Detailed description
PRIMARY OBJECTIVES: I. To use 3-dimensional (3D) quantitative mapping to determine whether differences in T2 spin parameters exist between the peritumoral area and normal brain in the contralateral hemisphere at baseline. II. To use 3D quantitative mapping to examine how differences between peritumoral and normal brain in the contralateral hemisphere change before and after treatment. SECONDARY OBJECTIVES: I. Determine whether T2 values might be useful in distinguishing non-enhancing components of the tumor as well as predicting response to treatment. II. Quantify T1 and proton density (PD) spin parameters of the peritumoral area and their differences before and after treatment. III. Examine post-contrast T1 spin parameters with perfusion characteristics as measured by an established dynamic susceptibility contrast (DSC) technique. IV. Examine differences in measured perfusion parameters (blood volume and mean transit time of each tumor) before and after treatment. OUTLINE: Within 21 days before standard of care chemotherapy and/or radiation therapy, patients undergo an MRI scan for the first set of images. Patients then receive either gadobutrol or gadobenate dimeglumine intravenously (IV) and undergo an MRI for the second set of images. All MRI scans take a total of 60 minutes to complete. Patients then repeat the MRI scans 120 days after standard of care chemotherapy and/or radiation therapy.
Interventions
Given IV
DRUGGadobutrol
Given IV
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
Sponsors
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least one enhancing lesion, aggregate of enhancing foci, and nonenhancing lesion measuring at least 1 cm in size and is suspected to be a high grade brain neoplasm * Patient is dispositioned to surgery, chemotherapy and/or radiation therapy * Patient is able to understand and give own consent to participate in the study
Exclusion criteria
* Contraindication to magnetic resonance imaging (MRI) as assessed by our standard of care magnetic resonance (MR) screening procedure, which includes implants or devices that are unsafe in the magnetic environment * Contraindication or history of allergy to Gadolinium-based (gadobutrol \[Gadovist\], gadobenate dimeglumine (Multihance\]) intravenous contrast * Verbal confirmation of pregnancy or a positive pregnancy test result in patient record * Prior partial (greater than 50%) or gross total resection of primary tumor * Prior chemotherapy or radiation treatment to brain
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differences in T2 spin parameters | Baseline | Will use 3-dimensional (3D) quantitative mapping to determine whether different in T2 spin parameters exist between the peritumoral area and normal brain in the contralateral hemisphere. If the data are normal, will calculate 95% confidence intervals around the mean paired difference in baseline T2 between the peritumoral and normal regions. If the data are not normally distributed, ordered statistics will be calculated, and bootstrapping will be used to estimate the 2.5th and 97.5th percentiles for the median. |
| Differences between peritumoral and normal brain | Baseline up to 120 days | Will use 3D quantitative mapping to examine how differences between peritumoral and normal brain in the contralateral hemisphere change before and after treatment. The regions of interest drawn on measured magnetic resonance (MR) spin parameter and MR perfusion parameter values will be grouped according to time point (pre- or post-treatment) and area (peritumoral, tumoral, and normal brain in the contralateral hemisphere). Descriptive statistics and boxplots of these measurements, paired differences between areas and paired differences between time points will be calculated. Will calculate 95% confidence intervals around the mean paired change between area differences at baseline and post-treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Usefulness of T2 values in distinguishing non-enhancing components of the tumor | Up to 120 days | Will use area under an receive operating curve to determine whether T2 values might be useful in distinguishing non-enhancing components of the tumor as well as predicting response to treatment. Paired data from all patients will be used in this analysis. |
| Quantification of T1 and proton density (PD) parameters | Baseline up to 120 days | Will quantify T1 and PD spin parameters of the peritumoral area and their differences before and after treatment. |
| Post-contrast T1 spin parameters with perfusion characteristics | Up to 120 days | Will examine post-contrast T1 spin parameters with perfusion characteristics as measured by an established dynamic susceptibility contrast technique. |
| Differences in measured perfusion parameters before and after treatment. | Baseline up to 120 days | Will examine differences in measured perfusion parameters before and after treatment. |
Countries
United States
Outcome results
None listed